» Cantech Holding, Inc. Announces Execution of Memorandum of Understanding With the TCM Group in Mexico

Cantech Holding, Inc., formerly Reve Technologies, Inc., (OTC PINK: BSSP) (the “Company” or “Cantech”) a development stage immunotherapeutic based technology company today announced it has executed a Memorandum of Understanding (the “MOU”) between TCM Group (“TCM”) and Cantech Intl. Group Mexico (“CIGM”), a to be newly formed unit of Cantech Holding, Inc. for the construction

» Cantech Holding, Inc. Announces Formal Negotiations With Zelor S.A.P.I., Mexico

Cantech Holding, Inc., formerly Reve Technologies, Inc. (BSSP) (the “Company” or “Cantech”) a development stage immunotherapeutic based technology company today announced it has received a Letter of Intent which proposes a business collaboration with newly formed Institute of Medicine of the conservation ZELOR S.A.P.I., located in Tijuana, B.C., Mexico. After ongoing discussions on August

» Cantech Holding, Inc. Announces Letter to Shareholders

Cantech Holding, Inc. f/k/a Reve Technologies, Inc. (BSSP) (the “Company” or “Cantech”) a development stage immunotherapeutic based technology company today announced a Letter to Shareholders updating current activities and outlining its corporate strategy for 2016, which will also become available and posted on its website at www.cantechholding.com. Preface: As previously reported the Company is

» Reve Announces Closing Exclusive License for Cantech’s IPF Irreversible Pepsin Fraction

We move ahead on our Immunotherapeutic IPF Platform Technology for Development, Manufacture and Commercialization. We pleased to announce that Reve Technologies, Inc. (BSSP) (the “Company” or “Reve”) a development stage technology company has effectively closed on its Purchase and Sale Agreement (the “Purchase Agreement”) with Canteck Pharma, Inc., a Delaware corporation (“Canteck” or “CKPH”)

» Reve Acquires Exclusive License for Canteck’s IPF Irreversable Pepsin Fraction Specific to Cancer Indication

Embarks on Shift to Immunotherapeutic IPF Platform Technology for Development, Manufacture and Commercialization Reve Technologies, Inc. (BSSP)  a development stage technology company is pleased to announce entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with Canteck Pharma, Inc., a Delaware corporation (“Canteck” or “CKPH”) and certain majority shareholders of CKPH. Canteck has